👉The table of contents so far is here.
Chapter 16: Economic Transition Plan I: Transition Period
16.8. Preparation for the establishment of pharmaceutical business organization, etc.
While pharmaceuticals can be classified as food in the broadest sense, their purpose and nature differ significantly from general food. Therefore, they are produced based on a pharmaceutical-specific production plan Division C, distinct from both the consumption plan for ordinary consumer goods and the production plan Division A for core industrial sectors and Division B for agriculture, forestry, and fisheries.
In this respect, since pharmaceuticals, in principle, should be supplied universally to maintain the life and health of all individuals worldwide, the principle is that key pharmaceuticals should be manufactured and supplied under a global common plan (see my article).
Furthermore, production plans for each zonal area will be independently formulated and implemented by a pharmaceutical business organization formed by integrating pharmaceutical companies. During the transitional period, the integration of individual pharmaceutical companies will be aimed at preparing for the establishment of the pharmaceutical business organization.
However, it is not necessary to integrate all existing pharmaceutical companies; the integration of companies responsible for manufacturing basic drugs such as representative disease treatments and vaccines that become prescription drugs for physicians, as well as a small number of specialized drugs for treating intractable diseases, will suffice.
Furthermore, the integration does not necessarily have to be company-wide; it would be acceptable to integrate after spinning off some departments into separate companies. The remaining departments not integrated, and pharmaceutical companies not involved in the manufacture of prescription drugs, will continue to exist as free production companies.
Incidentally, since the pharmaceutical business is inseparable from the existence of an independent and neutral drug regulatory and supervision system that conducts pre- and post-release reviews of drug efficacy and safety, preparations for the establishment of a regulatory and supervision agency completely separate from the pharmaceutical business organization will also be carried out in parallel.
This agency will not be a corporate entity but will basically have the characteristics of an administrative agency, and should have separate functions for pre-release efficacy and safety reviews and post-release safety reviews.
Of these, the latter, the post-release safety review agency, will have a quasi-judicial function for public protection, hearing specific drug-induced harm complaints from patients and providing relief to victims and taking action against those involved. Therefore, it will include not only medical and pharmaceutical experts but also lawyers well-versed in pharmaceutical laws.
👉The papers published on this blog are meant to expand upon my On Communism.
